 | • レポートコード：B-GIR08C5669 • 出版社/出版日：GlobalInfoResearch / 2019年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、100ページ • 納品方法：Eメール • 産業分類：Pharma & Healthcare |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Corporate User | ￥1,044,000 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは、NSCLC用標的薬BRAF阻害剤の世界市場について調べ、まとめました。種類別セグメントは、ダブラフェニブ、トラメチニブ、リフィラフェニブ、その他等、用途別セグメントは、等に区分しました。NSCLC用標的薬BRAF阻害剤の世界市場概観、企業動向、企業別NSCLC用標的薬BRAF阻害剤シェア、市場規模推移、市場規模予測（2019年-2024年）、主要地域分析（北米、ヨーロッパ、アジア等）、主要国分析（日本、中国、アメリカ等）データなどの情報が含まれています。 ・NSCLC用標的薬BRAF阻害剤の市場概観 ・NSCLC用標的薬BRAF阻害剤の企業概要（事業概要、製品種類、販売量、価格、売上、市場シェア等） ・NSCLC用標的薬BRAF阻害剤の企業別販売動向、市場シェア、市場集中度、競争動向 ・NSCLC用標的薬BRAF阻害剤の世界市場規模 ・NSCLC用標的薬BRAF阻害剤の北米市場分析（アメリカ、カナダ、メキシコ等） ・NSCLC用標的薬BRAF阻害剤のアメリカ市場規模推移 ・NSCLC用標的薬BRAF阻害剤のカナダ市場規模推移 ・NSCLC用標的薬BRAF阻害剤のメキシコ市場規模推移 ・NSCLC用標的薬BRAF阻害剤のヨーロッパ市場分析（ドイツ、イギリス、ロシア、フランス、イタリア等） ・NSCLC用標的薬BRAF阻害剤のドイツ市場規模推移 ・NSCLC用標的薬BRAF阻害剤のイギリス市場規模推移 ・NSCLC用標的薬BRAF阻害剤のロシア市場規模推移 ・NSCLC用標的薬BRAF阻害剤のアジア太平洋市場分析（日本、中国、韓国、インド、東南アジア等） ・NSCLC用標的薬BRAF阻害剤の日本市場規模推移 ・NSCLC用標的薬BRAF阻害剤の中国市場規模推移 ・NSCLC用標的薬BRAF阻害剤の韓国市場規模推移 ・NSCLC用標的薬BRAF阻害剤のインド市場規模推移 ・NSCLC用標的薬BRAF阻害剤の東南アジア市場規模推移 ・NSCLC用標的薬BRAF阻害剤の南米市場分析（ブラジル、アルゼンチン等） ・NSCLC用標的薬BRAF阻害剤の中東・アフリカ市場分析（サウジアラビア、UAE、南アフリカ等） ・NSCLC用標的薬BRAF阻害剤の種類別分析/販売量、売上、市場シェア（ダブラフェニブ、トラメチニブ、リフィラフェニブ、その他） ・NSCLC用標的薬BRAF阻害剤の用途別分析/市場規模（） ・NSCLC用標的薬BRAF阻害剤の市場予測2019年-2024年（地域別予測、種類別予測、用途別予測） ・NSCLC用標的薬BRAF阻害剤の販売チャネル・代理店・貿易業者・ディーラー分析 |
Scope of the Report:
The global Targeted Drug BRAF Inhibitors for NSCLC market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Targeted Drug BRAF Inhibitors for NSCLC.
Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
This report studies the Targeted Drug BRAF Inhibitors for NSCLC market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Targeted Drug BRAF Inhibitors for NSCLC market by product type and applications/end industries.
Market Segment by Companies, this report covers
BeiGene
Novartis
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Dabrafenib
Trametinib
Lifirafenib
Other
Market Segment by Applications, can be divided into
Squamous Cell Carcinoma of NSCLC
Adenocarcinoma of NSCLC
Large Cell Carcinoma of NSCLC
Table of Contents
1 Targeted Drug BRAF Inhibitors for NSCLC Market Overview
1.1 Product Overview and Scope of Targeted Drug BRAF Inhibitors for NSCLC
1.2 Classification of Targeted Drug BRAF Inhibitors for NSCLC by Types
1.2.1 Global Targeted Drug BRAF Inhibitors for NSCLC Revenue Comparison by Types (2019-2024)
1.2.2 Global Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Share by Types in 2018
1.2.3 Dabrafenib
1.2.4 Trametinib
1.2.5 Lifirafenib
1.2.6 Other
1.3 Global Targeted Drug BRAF Inhibitors for NSCLC Market by Application
1.3.1 Global Targeted Drug BRAF Inhibitors for NSCLC Market Size and Market Share Comparison by Applications (2014-2024)
1.3.2 Squamous Cell Carcinoma of NSCLC
1.3.3 Adenocarcinoma of NSCLC
1.3.4 Large Cell Carcinoma of NSCLC
1.4 Global Targeted Drug BRAF Inhibitors for NSCLC Market by Regions
1.4.1 Global Targeted Drug BRAF Inhibitors for NSCLC Market Size (Million USD) Comparison by Regions (2014-2024)
1.4.1 North America (USA, Canada and Mexico) Targeted Drug BRAF Inhibitors for NSCLC Status and Prospect (2014-2024)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Targeted Drug BRAF Inhibitors for NSCLC Status and Prospect (2014-2024)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Targeted Drug BRAF Inhibitors for NSCLC Status and Prospect (2014-2024)
1.4.4 South America (Brazil, Argentina, Colombia) Targeted Drug BRAF Inhibitors for NSCLC Status and Prospect (2014-2024)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Targeted Drug BRAF Inhibitors for NSCLC Status and Prospect (2014-2024)
1.5 Global Market Size of Targeted Drug BRAF Inhibitors for NSCLC (2014-2024)
2 Manufacturers Profiles
2.1 BeiGene
2.1.1 Business Overview
2.1.2 Targeted Drug BRAF Inhibitors for NSCLC Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 BeiGene Targeted Drug BRAF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
2.2 Novartis
2.2.1 Business Overview
2.2.2 Targeted Drug BRAF Inhibitors for NSCLC Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Novartis Targeted Drug BRAF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
3 Global Targeted Drug BRAF Inhibitors for NSCLC Market Competition, by Players
3.1 Global Targeted Drug BRAF Inhibitors for NSCLC Revenue and Share by Players (2014-2019)
3.2 Market Concentration Rate
3.2.1 Top 5 Targeted Drug BRAF Inhibitors for NSCLC Players Market Share
3.2.2 Top 10 Targeted Drug BRAF Inhibitors for NSCLC Players Market Share
3.3 Market Competition Trend
4 Global Targeted Drug BRAF Inhibitors for NSCLC Market Size by Regions
4.1 Global Targeted Drug BRAF Inhibitors for NSCLC Revenue and Market Share by Regions
4.2 North America Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
4.3 Europe Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
4.4 Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
4.5 South America Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
4.6 Middle East and Africa Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
5 North America Targeted Drug BRAF Inhibitors for NSCLC Revenue by Countries
5.1 North America Targeted Drug BRAF Inhibitors for NSCLC Revenue by Countries (2014-2019)
5.2 USA Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
5.3 Canada Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
5.4 Mexico Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
6 Europe Targeted Drug BRAF Inhibitors for NSCLC Revenue by Countries
6.1 Europe Targeted Drug BRAF Inhibitors for NSCLC Revenue by Countries (2014-2019)
6.2 Germany Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
6.3 UK Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
6.4 France Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
6.5 Russia Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
6.6 Italy Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
7 Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Revenue by Countries
7.1 Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Revenue by Countries (2014-2019)
7.2 China Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
7.3 Japan Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
7.4 Korea Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
7.5 India Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
7.6 Southeast Asia Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
8 South America Targeted Drug BRAF Inhibitors for NSCLC Revenue by Countries
8.1 South America Targeted Drug BRAF Inhibitors for NSCLC Revenue by Countries (2014-2019)
8.2 Brazil Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
8.3 Argentina Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
8.4 Colombia Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
9 Middle East and Africa Revenue Targeted Drug BRAF Inhibitors for NSCLC by Countries
9.1 Middle East and Africa Targeted Drug BRAF Inhibitors for NSCLC Revenue by Countries (2014-2019)
9.2 Saudi Arabia Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
9.3 UAE Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
9.4 Egypt Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
9.5 Nigeria Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
9.6 South Africa Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
10 Global Targeted Drug BRAF Inhibitors for NSCLC Market Segment by Type
10.1 Global Targeted Drug BRAF Inhibitors for NSCLC Revenue and Market Share by Type (2014-2019)
10.2 Global Targeted Drug BRAF Inhibitors for NSCLC Market Forecast by Type (2019-2024)
10.3 Dabrafenib Revenue Growth Rate (2014-2024)
10.4 Trametinib Revenue Growth Rate (2014-2024)
10.5 Lifirafenib Revenue Growth Rate (2014-2024)
10.6 Other Revenue Growth Rate (2014-2024)
11 Global Targeted Drug BRAF Inhibitors for NSCLC Market Segment by Application
11.1 Global Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Share by Application (2014-2019)
11.2 Targeted Drug BRAF Inhibitors for NSCLC Market Forecast by Application (2019-2024)
11.3 Squamous Cell Carcinoma of NSCLC Revenue Growth (2014-2019)
11.4 Adenocarcinoma of NSCLC Revenue Growth (2014-2019)
11.5 Large Cell Carcinoma of NSCLC Revenue Growth (2014-2019)
12 Global Targeted Drug BRAF Inhibitors for NSCLC Market Size Forecast (2019-2024)
12.1 Global Targeted Drug BRAF Inhibitors for NSCLC Market Size Forecast (2019-2024)
12.2 Global Targeted Drug BRAF Inhibitors for NSCLC Market Forecast by Regions (2019-2024)
12.3 North America Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Forecast (2019-2024)
12.4 Europe Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Forecast (2019-2024)
12.5 Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Forecast (2019-2024)
12.6 South America Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Forecast (2019-2024)
12.7 Middle East and Africa Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Forecast (2019-2024)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
Figure Targeted Drug BRAF Inhibitors for NSCLC Picture
Table Product Specifications of Targeted Drug BRAF Inhibitors for NSCLC
Table Global Targeted Drug BRAF Inhibitors for NSCLC and Revenue (Million USD) Market Split by Product Type
Figure Global Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Share by Types in 2018
Figure Dabrafenib Picture
Figure Trametinib Picture
Figure Lifirafenib Picture
Figure Other Picture
Table Global Targeted Drug BRAF Inhibitors for NSCLC Revenue (Million USD) by Application (2014-2024)
Figure Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Share by Applications in 2018
Figure Squamous Cell Carcinoma of NSCLC Picture
Figure Adenocarcinoma of NSCLC Picture
Figure Large Cell Carcinoma of NSCLC Picture
Table Global Market Targeted Drug BRAF Inhibitors for NSCLC Revenue (Million USD) Comparison by Regions 2014-2024
Figure North America Targeted Drug BRAF Inhibitors for NSCLC Revenue (Million USD) and Growth Rate (2014-2024)
Figure Europe Targeted Drug BRAF Inhibitors for NSCLC Revenue (Million USD) and Growth Rate (2014-2024)
Figure Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Revenue (Million USD) and Growth Rate (2014-2024)
Figure South America Targeted Drug BRAF Inhibitors for NSCLC Revenue (Million USD) and Growth Rate (2014-2024)
Figure Middle East and Africa Targeted Drug BRAF Inhibitors for NSCLC Revenue (Million USD) and Growth Rate (2014-2024)
Figure Global Targeted Drug BRAF Inhibitors for NSCLC Revenue (Million USD) and Growth Rate (2014-2024)
Table BeiGene Basic Information, Manufacturing Base and Competitors
Table BeiGene Targeted Drug BRAF Inhibitors for NSCLC Type and Applications
Table BeiGene Targeted Drug BRAF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
Table Novartis Basic Information, Manufacturing Base and Competitors
Table Novartis Targeted Drug BRAF Inhibitors for NSCLC Type and Applications
Table Novartis Targeted Drug BRAF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
Table Global Targeted Drug BRAF Inhibitors for NSCLC Revenue (Million USD) by Players (2014-2019)
Table Global Targeted Drug BRAF Inhibitors for NSCLC Revenue Share by Players (2014-2019)
Figure Global Targeted Drug BRAF Inhibitors for NSCLC Revenue Share by Players in 2017
Figure Global Targeted Drug BRAF Inhibitors for NSCLC Revenue Share by Players in 2018
Figure Global Top 5 Players Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Share in 2018
Figure Global Top 10 Players Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Share in 2018
Figure Global Targeted Drug BRAF Inhibitors for NSCLC Revenue (Million USD) and Growth Rate (%) (2014-2019)
Table Global Targeted Drug BRAF Inhibitors for NSCLC Revenue (Million USD) by Regions (2014-2019)
Table Global Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Share by Regions (2014-2019)
Figure Global Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Share by Regions (2014-2019)
Figure Global Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Share by Regions in 2018
Figure North America Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure Europe Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure South America Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure Middle East and Africa Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Table North America Targeted Drug BRAF Inhibitors for NSCLC Revenue by Countries (2014-2019)
Table North America Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Share by Countries (2014-2019)
Figure North America Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Share by Countries (2014-2019)
Figure North America Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Share by Countries in 2018
Figure USA Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure Canada Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure Mexico Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Table Europe Targeted Drug BRAF Inhibitors for NSCLC Revenue (Million USD) by Countries (2014-2019)
Figure Europe Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Share by Countries (2014-2019)
Figure Europe Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Share by Countries in 2018
Figure Germany Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure UK Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure France Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure Russia Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure Italy Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Table Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Revenue (Million USD) by Countries (2014-2019)
Figure Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Share by Countries (2014-2019)
Figure Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Share by Countries in 2018
Figure China Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure Japan Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure Korea Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure India Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure Southeast Asia Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Table South America Targeted Drug BRAF Inhibitors for NSCLC Revenue by Countries (2014-2019)
Table South America Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Share by Countries (2014-2019)
Figure South America Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Share by Countries (2014-2019)
Figure South America Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Share by Countries in 2018
Figure Brazil Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure Argentina Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure Colombia Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Table Middle East and Africa Targeted Drug BRAF Inhibitors for NSCLC Revenue (Million USD) by Countries (2014-2019)
Table Middle East and Africa Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Share by Countries (2014-2019)
Figure Middle East and Africa Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Share by Countries (2014-2019)
Figure Middle East and Africa Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Share by Countries in 2018
Figure Saudi Arabia Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure UAE Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure Egypt Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure Nigeria Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Figure South Africa Targeted Drug BRAF Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
Table Global Targeted Drug BRAF Inhibitors for NSCLC Revenue (Million USD) by Type (2014-2019)
Table Global Targeted Drug BRAF Inhibitors for NSCLC Revenue Share by Type (2014-2019)
Figure Global Targeted Drug BRAF Inhibitors for NSCLC Revenue Share by Type (2014-2019)
Figure Global Targeted Drug BRAF Inhibitors for NSCLC Revenue Share by Type in 2018
Table Global Targeted Drug BRAF Inhibitors for NSCLC Revenue Forecast by Type (2019-2024)
Figure Global Targeted Drug BRAF Inhibitors for NSCLC Market Share Forecast by Type (2019-2024)
Figure Global Dabrafenib Revenue Growth Rate (2014-2019)
Figure Global Trametinib Revenue Growth Rate (2014-2019)
Figure Global Lifirafenib Revenue Growth Rate (2014-2019)
Figure Global Other Revenue Growth Rate (2014-2019)
Table Global Targeted Drug BRAF Inhibitors for NSCLC Revenue by Application (2014-2019)
Table Global Targeted Drug BRAF Inhibitors for NSCLC Revenue Share by Application (2014-2019)
Figure Global Targeted Drug BRAF Inhibitors for NSCLC Revenue Share by Application (2014-2019)
Figure Global Targeted Drug BRAF Inhibitors for NSCLC Revenue Share by Application in 2018
Table Global Targeted Drug BRAF Inhibitors for NSCLC Revenue Forecast by Application (2019-2024)
Figure Global Targeted Drug BRAF Inhibitors for NSCLC Market Share Forecast by Application (2019-2024)
Figure Global Squamous Cell Carcinoma of NSCLC Revenue Growth Rate (2014-2019)
Figure Global Adenocarcinoma of NSCLC Revenue Growth Rate (2014-2019)
Figure Global Large Cell Carcinoma of NSCLC Revenue Growth Rate (2014-2019)
Figure Global Targeted Drug BRAF Inhibitors for NSCLC Revenue (Million USD) and Growth Rate Forecast (2019-2024)
Table Global Targeted Drug BRAF Inhibitors for NSCLC Revenue (Million USD) Forecast by Regions (2019-2024)
Figure Global Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Share Forecast by Regions (2019-2024)
Figure North America Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Forecast (2019-2024)
Figure Europe Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Forecast (2019-2024)
Figure Asia-Pacific Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Forecast (2019-2024)
Figure South America Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Forecast (2019-2024)
Figure Middle East and Africa Targeted Drug BRAF Inhibitors for NSCLC Revenue Market Forecast (2019-2024)
NSCLC用標的薬物MEK阻害剤の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024） Scope of the Report: The global Targeted Drug MEK Inhibitors for NSCLC market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, especia…- NSCLC用標的薬剤VEGFR2阻害剤の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024） Scope of the Report: The global Targeted Drug VEGFR2 Inhibitors for NSCLC market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, espe…
- NSCLC用標的薬物HER2阻害剤の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024） Scope of the Report: The global Targeted Drug HER2 Inhibitors for NSCLC market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, especi…
- NSCLC用標的薬剤ROS1阻害剤の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024） Scope of the Report: The global Targeted Drug ROS1 Inhibitors for NSCLC market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, especi…
- NSCLC用標的薬物VEGF阻害剤の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024） Scope of the Report: The global Targeted Drug VEGF Inhibitors for NSCLC market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, especi…